| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - Dextroamphetamine is the dextrorotary stereoisomer of the amphetamine molecule, which can take two different forms. It is a slightly polar, weak base and is lipophilic. (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Yamada H, Baba T, Hirata Y, Oguri K, Yoshimura H: Studies on N-demethylation of methamphetamine by liver microsomes of guinea-pigs and rats: the role of flavin-containing mono-oxygenase and cytochrome P-450 systems. Xenobiotica. 1984 Nov;14(11):861-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6506758 # Warneke L: Psychostimulants in psychiatry. Can J Psychiatry. 1990 Feb;35(1):3-10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2180548 # Wagner GJ, Rabkin R: Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. J Clin Psychiatry. 2000 Jun;61(6):436-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10901342 # Martinsson L, Yang X, Beck O, Wahlgren NG, Eksborg S: Pharmacokinetics of dexamphetamine in acute stroke. Clin Neuropharmacol. 2003 Sep-Oct;26(5):270-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14520168 # Butefisch CM, Davis BC, Sawaki L, Waldvogel D, Classen J, Kopylev L, Cohen LG: Modulation of use-dependent plasticity by d-amphetamine. Ann Neurol. 2002 Jan;51(1):59-68. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11782985 (en)
|
| http://linked.open...gy/drugbank/group
| - approved (en)
- illicit (en)
|
| http://linked.open...drugbank/halfLife
| - 10-28 hours (average is approximately 12 hours) (en)
|
| http://linked.open...ugbank/indication
| - Used to treat attention deficit hyperactivity disorder (ADHD). (en)
|
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - The exact mechanism of action is not known. Dextroamphetamine stimulates the release of norepinephrine from central adrenergic receptors. At higher dosages, it causes release of dopamine from the mesocorticolimbic system and the nigrostriatal dopamine systems by reversal of the monoamine transporters. Dextroamphetamine may also act as a direct agonist on central 5-HT receptors and may inhibit monoamine oxidase (MAO). In the periphery, amphetamines are believed to cause the release of noradrenaline by acting on the adrenergic nerve terminals and alpha- and beta-receptors. Modulation of serotonergic pathways may contribute to the calming affect. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open.../drugbank/synonym
| - Dextroamphetamine (en)
- (+)-(S)-amphetamine (en)
- (S)-amphetamine (en)
- d-amphetamine (en)
- dexamphetamine (en)
- (+)-Amphetamine (en)
- (+)-alpha-Methylphenethylamine (en)
- (+)-alpha-Methylphenylethylamine (en)
- (AlphaS)-alpha-methylbenzeneethanamine (en)
- (S)-(+)-Amphetamine (en)
- (S)-(+)-beta-Phenylisopropylamine (en)
- (S)-1-Phenyl-2-aminopropane (en)
- (S)-1-Phenyl-2-propylamine (en)
- (S)-alpha-Methylbenzeneethanamine (en)
|
| http://linked.open...drugbank/toxicity
| - In rats, the oral LD50 of dextroamphetamine sulfate is 96.8 mg/kg. Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma. (en)
|
| http://linked.open.../drug/hasAHFSCode
| |
| http://linked.open.../drugbank/mixture
| |
| http://linked.open...ogy/drugbank/salt
| |
| http://linked.open...ynthesisReference
| - Nabenhauer, F.P.; US. Patent 2,276,508; March 17,1942; assigned to Smith, Kline & French Laboratories. (en)
|
| http://linked.open...y/mesh/hasConcept
| |
| foaf:page
| |
| http://linked.open...ugbank/IUPAC-Name
| |
| http://linked.open...gy/drugbank/InChI
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...noisotopic-Weight
| |
| http://linked.open...y/drugbank/SMILES
| |
| http://linked.open.../Water-Solubility
| |
| http://linked.open...ogy/drugbank/logP
| |
| http://linked.open...ogy/drugbank/logS
| |
| http://linked.open...logy/drugbank/pKa
| |
| http://linked.open...nd-Acceptor-Count
| |
| http://linked.open...-Bond-Donor-Count
| |
| http://linked.open...drugbank/InChIKey
| |
| http://linked.open...urface-Area--PSA-
| |
| http://linked.open...nk/Polarizability
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)